Neuronix to present data on NeuroAD device at Alzheimer's Association International Conference

Neuronix, which has developed an innovative medical device technology for the treatment of Alzheimer's Disease (AD), announces today that it will present at the leading Alzheimer's Association International Conference (AAIC), in Boston, United States.

The company will present clinical trials data to thousands of participants, including physicians, researchers, care providers and leading figures in the field from various countries around the world.

Neuronix has developed the only treatment existing today that combines magnetic simulation (TMS) and cognitive exercise, with significant success. The treatment significantly improves the cognitive status of the patients, as well as slows the disease progression, therefore improving the life of the patient and their family members.

The new technology is non-invasive and safe for an effective treatment of the disease. Using the NeuroAD device, daily treatment is carried out, combining precise and timed electromagnetic pulses and cognitive tasks. The stimulation and exercise have been developed to simultaneously affect the same area in the brain.

The treatment is six weeks long, and it consists of five daily one-hour sessions per week.

The clinical trials, in Harvard University in the United States and Assaf Harofeh Hospital in Israel, have shown the technology to be more effective than current medications, and have proven its safety also when used in combination with existing treatments. Additionally, a slower degenerative progression was observed over time, while the treatment can be repeated every 9-12 months.

NeuroAD is CE approved for marketing in Europe, as well as in Israel. The company has already commenced a pivotal study in the United States in order to receive FDA approval.

Alzheimer's disease is incurable, and it is one of the most expensive diseases for health systems worldwide, with annual expenses estimated at 600 billion dollars. The number of AD patients globally is 30-35 million, and this number is expected to double by 2030.